Recurrent bladder cancer can be detected through measuring a certain protein present in the urine. Where the US is concerned, bladder cancer is reported to be the fifth most malignant, which recorded 63,210 new cases in the year 2005 year alone, with over 13,000 deaths. The country has a total of 500,000 patients with a bladder cancer history, and the chances of its recurrence is between 50% and 90%.
There is no known procedure of monitoring this ailment which is 100% perfect. The standard approach is the cystoscopy approach. The cytologic (cell) analysis has a reputation for variability and poor sensitivity while interpreting results. A noninvasive urine test’s clinical utility was examined by the Anderson Cancer Center’s H. Barton Grossman. This is a test for the protein NMP22 which helps in detecting recurrent cancer.The study involved 668 patients who had a history of the ailment. The urine samples were tested for the NMP22 protein before the cystoscopy. As many as 103 bladder cancer cases were identified, and 91.3% of them were identified by cystoscopy. When cystoscopy was combined with NMP22, about 99% of the malignancies were detected, thus proving the efficacy of the combination.
